Conatus Pharmaceuticals (CNAT) Tops Q3 EPS by 3c

Conatus Pharmaceuticals (NASDAQ: CNAT) reported Q3 EPS of ($0.31), $0.03 better than the analyst estimate of ($0.34).

For earnings history and earnings-related data on Conatus Pharmaceuticals (CNAT) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Bath & Body Works rises as Citi upgrades stock ahead of earnings
• Amer Sports, Inc. (AS) Tops Q2 EPS by 11c; raises guidance